Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

Sruamsiri, Rosarin, Chaiyakunapruk, Nathorn, Pakakasama, Samart, Sirireung, Somtawin, Sripaiboonkij, Nintita, Bunworasate, Udomsak and Hongeng, Suradej (2013) Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program. Bmc Health Services Research, 13 Article 45: . doi:10.1186/1472-6963-13-45


Author Sruamsiri, Rosarin
Chaiyakunapruk, Nathorn
Pakakasama, Samart
Sirireung, Somtawin
Sripaiboonkij, Nintita
Bunworasate, Udomsak
Hongeng, Suradej
Title Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program
Journal name Bmc Health Services Research   Check publisher's open access policy
ISSN 1472-6963
Publication date 2013-02-05
Year available 2013
Sub-type Article (original research)
DOI 10.1186/1472-6963-13-45
Open Access Status DOI
Volume 13
Issue Article 45
Total pages 12
Place of publication BioMed Central
Publisher London, United Kingdom
Collection year 2014
Language eng
Formatted abstract
Background
Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand.
Methods
A Markov model was used to estimate the relevant costs and health outcomes over the patients’ lifetimes using a societal perspective. All future costs and outcomes were discounted at a rate of 3% per annum. The efficacy of RI-HSCT was based a clinical trial including a total of 18 thalassemia patients. Utility values were derived directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest were lifetime costs, quality adjusted life-years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in US ($) per QALY gained. One-way and probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of parameter uncertainty.
Results
In base case analysis, the RI-HSCT group had a better clinical outcomes and higher lifetime costs. The incremental cost per QALY gained was US $ 3,236 per QALY. The acceptability curve showed that the probability of RI-HSCT being cost-effective was 71% at the willingness to pay of 1 time of Thai Gross domestic product per capita (GDP per capita), approximately US $ 4,210 per QALY gained. The most sensitive parameter was utility of severe thalassemia patients without cardiac complication patients.
Conclusion
At a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective treatment for adolescent and young adult with severe thalassemia in Thailand compared to BT-ICT.

Keyword Cost-utility analysis
Reduced intensity transplantation
Thalassemia
Adolescence
Adult
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 31 Mar 2013, 01:12:08 EST by System User on behalf of School of Public Health